Executive Director, Cell & Gene Therapy, Labcorp
BIOGRAPHY
Speakers
-
Christos J. Petropoulos, PhD
Chief Scientific Officer, Monogram Biosciences and Vice President, Corporate Research and Development, LabcorpBIOGRAPHY -
Irene Bacalocostantis
Executive Director, Regulatory Affairs, Project and Portfolio Management and Manufacturing, Companion Diagnostics (CDx), LabcorpBIOGRAPHY -
Taylor Jensen, PhD
Vice President, Head of Oncology Science, LabcorpBIOGRAPHY
Abstract
Watch the third of a three-part roundtable series that focus on approaches to accelerating your advanced therapy program by leveraging the combination of innovative technology and deep cross-industry insights from our cell and gene therapy scientists and operational leaders.
In this roundtable, the panel focus on the adoption of companion diagnostics strategies for your clinical cell and gene therapy development efforts. Specific areas of discussion include:
- The evolving landscape of companion diagnostics in the field of cell and gene therapy
- The role of anti-AAV neutralizing and total antibody assessment in clinical trials, including their potential as companion diagnostics for gene therapies
- Regulatory considerations for the development of cell and gene therapies and trends with certain regulatory bodies
- Considerations for commercializing a companion diagnostic
Watch roundtable 1: Key Considerations for Driving Gene Therapy Programs Successfully Through IND/CTA and Beyond
Watch roundtable 2: Accelerating Cell Therapy Clinical Trials With Comprehensive Biomarker-Driven Strategies
Watch roundtable 3: Companion Diagnostic Approaches in the Development of Cell and Gene Therapies
Watch roundtable 2: Accelerating Cell Therapy Clinical Trials With Comprehensive Biomarker-Driven Strategies
Watch roundtable 3: Companion Diagnostic Approaches in the Development of Cell and Gene Therapies